After 1 month of fremanezumab treatment, the risk for new-onset headache declined significantly across all weather patterns, ...

Vedana Therapeutics emerged from stealth with a $46M Series A.

Vedana Therapeutics ("Vedana"), a biotechnology company developing next-generation therapies for migraine prevention, today ...

Eli Lilly and Co on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often ...

After being on a slew of non-migraine-specific medications without the benefits I expected, I felt frustrated and hopeless — until doing research for a neurobiology class in college. Here, I gave a ...

Like Lundbeck’s bocunebart, Vedana’s clinical pipeline targets PACAP – an approach that has shown varying levels of success ...

ORLANDO, Fla. — Use of calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine was associated with a 19% increase in adjusted odds of fracture over 1 year. Results of a large ...

Migraine researchers and clinicians are growing excited about a new class of drugs called Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies, which are showing promise in treating ...

A new study suggests that gepants, a newer class of migraine medications may help relieve vertigo, dizziness, and balance ...

Decreased tear levels of CGRP and SP correlate with dry eye disease severity and symptoms. Study involved 12 healthy volunteers and 16 DED patients, highlighting significant neuropeptide level ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...